Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label dose-optimization trial of Zalypsis (PM00104) in relapsed/refractory multiple myeloma
2009-016054-40Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Nov 2009
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zalypsis in multiple myeloma (MM) (2 arms), sponsored by PharmaMar. Primary endpoints: Safety and tolerability of PM00104 (dose optimization), Antitumor efficacy of PM00104 and 2 more. Started Nov 2009; status: completed.
02
Drugs
zalypsis
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2009-016054-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016054-40.